When it comes to MRD, AML ≠ ALL

Research output: Contribution to journalComment/debatepeer-review

11 Scopus citations


Only the most specific main institutional affiliation is listed for Inside Blood authors, without indications of subdivisions, departments, parent institutions, or postal/geographic information. Please confirm or correct affiliation. Minimal residual disease (MRD) detection is standard of care in acute lymphoblastic leukemia (ALL), but not acute myeloid leukemia (AML). In this issue of Blood, anAML trial by Loken and colleagues from the Children's Oncology Group (COG) retrospectively demonstrates clinical significance of MRD. These data reaffirm that AML-MRDis unlike ALL-MRD.

Original languageEnglish (US)
Pages (from-to)1536-1537
Number of pages2
Issue number8
StatePublished - Aug 23 2012

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'When it comes to MRD, AML ≠ ALL'. Together they form a unique fingerprint.

Cite this